85
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2008
Study Completion Date
May 31, 2008
2.5 mg NX-1207
Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
0.125 mg NX-1207
Low dose; single intraprostatic injection of 0.125 mg NX-1207
finasteride
Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
Nymox Investigational Site, Huntsville
Nymox Investigational Site, Tucson
Nymox Investigational Site, Little Rock
Nymox Investigational Site, Anaheim
Nymox Investigational Site, Atherton
Nymox Investigational Site, Long Beach
Nymox Investigational Site, Modesto
Nymox Investigational Site, Newport Beach
Nymox Investigational Site, Denver
Nymox Investigational Site, New Britain
Nymox Investigational Site, Sarasota
Nymox Investigational Site, Greenwood
Nymox Investigational Site, Jeffersonville
Nymox Investigational Site, Shreveport
Nymox Investigational Site, Missoula
Nymox Investigational Site, Las Vegas
Nymox Investigational Site, Lawrenceville
Nymox Investigational Site, Marlton
Nymox Investigational Site, Voorhees Township
Nymox Investigational Site, Garden City
Nymox Investigational Site, Poughkeepsie
Nymox Investigational Site, Staten Island
Nymox Investigational Site, Lancaster
Nymox Investigational Site, Myrtle Beach
Nymox Investigational Site, Germantown
Nymox Investigational Site, Arlington
Nymox Investigational Site, Brownsville
Nymox Investigational Site, Dallas
Nymox Investigational Site, McAllen
Nymox Investigational Site, San Antonio
Lead Sponsor
Nymox Corporation
INDUSTRY